Company
Takeda Pharmaceutical Company Limited
Headquarters: Tokyo, Japan
Founded: Doshomachi, Osaka, Japan June 12, 1781
Employees: 47,099
CEO: Mr. Christophe Weber
Market Cap
¥6.507 Trillion
JPY as of Jan. 1, 2025
US$41.47 Billion
Takeda Pharmaceutical Company Limited Categories
Japan Healthcare Drug Manufacturers—Specialty & GenericJapan Healthcare Japan Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $75.33 B |
| MERCK Kommanditgesellschaft auf Aktien | $65.17 B |
| Haleon plc | $42.16 B |
| Teva Pharmaceutical Industries Limited | $18.95 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | ¥4.546 T |
| EBITDA | ¥1.170 T |
| Gross Profit TTM | ¥2.837 T |
| Profit Margin | 6.38% |
| Operating Margin | 20.54% |
| Quarterly Revenue Growth | 12.70% |
Stocks & Indices
Takeda Pharmaceutical Company Limited has the following listings and related stock indices.
Stock: JPX: 4502 wb_incandescent
Stock: FSX: TKD wb_incandescent
Stock: OTC: TKPHF wb_incandescent
Stock: NYSE: TAK wb_incandescent
Stock: BMV: TAKN wb_incandescent
Stock: XSTU: TKDA wb_incandescent
Stock: FSX: TKDA wb_incandescent
Key People
Founder(s): Chobei Takeda I
Yasuchika Hasegawa (Chairman of the Board) Christophe Weber (President & CEO)